These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 23909679

  • 21. Late rebound of infantile hemangioma after cessation of oral propranolol.
    Shehata N, Powell J, Dubois J, Hatami A, Rousseau E, Ondrejchak S, McCuaig C.
    Pediatr Dermatol; 2013; 30(5):587-91. PubMed ID: 24016283
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial.
    Zaher H, Rasheed H, Esmat S, Hegazy RA, Gawdat HI, Hegazy RA, El-Komy M, Abdelhalim DM.
    Eur J Dermatol; 2013; 23(5):646-52. PubMed ID: 24135427
    [Abstract] [Full Text] [Related]

  • 24. Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
    Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK.
    Ann Surg; 2012 Jul; 256(1):146-56. PubMed ID: 22580939
    [Abstract] [Full Text] [Related]

  • 25. Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study.
    Tanabe H, Sahashi K, Kitano T, Tomita Y, Saito AM, Hirose H.
    JAMA Ophthalmol; 2013 Dec; 131(12):1617-22. PubMed ID: 24158615
    [Abstract] [Full Text] [Related]

  • 26. Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report.
    Przewratil P, Sitkiewicz A, Wyka K, Andrzejewska E.
    Pediatr Dermatol; 2009 Dec; 26(4):399-404. PubMed ID: 19689513
    [Abstract] [Full Text] [Related]

  • 27. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.
    Şen HS, Yalçın B, Canpınar H, Ocak S, Akyüz C.
    Turk J Pediatr; 2020 Dec; 62(6):979-985. PubMed ID: 33372436
    [Abstract] [Full Text] [Related]

  • 28. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic.
    Bertrand J, Sammour R, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Boutin C, Bortoluzzi P, Laberge LC, Powell J.
    J Cutan Med Surg; 2012 Dec; 16(2):115-21. PubMed ID: 22513064
    [Abstract] [Full Text] [Related]

  • 29. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.
    Hermans DJ, Bauland CG, Zweegers J, van Beynum IM, van der Vleuten CJ.
    Br J Dermatol; 2013 Apr; 168(4):837-43. PubMed ID: 23278381
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Periocular infantile haemangioma and the role of propranolol.
    Chaudhry TA, Kamal M, Ahmad K.
    J Coll Physicians Surg Pak; 2013 Aug; 23(8):593-5. PubMed ID: 23930881
    [Abstract] [Full Text] [Related]

  • 32. [Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma].
    Yuan WL, Wang XK.
    Shanghai Kou Qiang Yi Xue; 2022 Aug; 31(4):400-405. PubMed ID: 36710554
    [Abstract] [Full Text] [Related]

  • 33. Propranolol for infantile haemangioma: striking effect in the first weeks.
    Katona G, Csákányi Z, Gács E, Szalai Z, Ráth G, Gerlinger I.
    Int J Pediatr Otorhinolaryngol; 2012 Dec; 76(12):1746-50. PubMed ID: 22944359
    [Abstract] [Full Text] [Related]

  • 34. Propranolol treatment for infantile hemangioma: a case series of sixty-two patients.
    Stringari G, Barbato G, Zanzucchi M, Marchesi M, Cerasoli G, Tchana B, Gritti A, Boccaletti V, Lombardi AA, Carano N.
    Pediatr Med Chir; 2016 Jun 27; 38(2):113. PubMed ID: 27345601
    [Abstract] [Full Text] [Related]

  • 35. Diagnosis and management of infantile hemangiomas.
    Püttgen KB.
    Pediatr Clin North Am; 2014 Apr 27; 61(2):383-402. PubMed ID: 24636652
    [Abstract] [Full Text] [Related]

  • 36. A randomized, controlled trial of oral propranolol in infantile hemangioma.
    Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ.
    N Engl J Med; 2015 Feb 19; 372(8):735-46. PubMed ID: 25693013
    [Abstract] [Full Text] [Related]

  • 37. β-blockers for infantile hemangiomas: a single-institution experience.
    Blatt J, Morrell DS, Buck S, Zdanski C, Gold S, Stavas J, Powell C, Burkhart CN.
    Clin Pediatr (Phila); 2011 Aug 19; 50(8):757-63. PubMed ID: 21525081
    [Abstract] [Full Text] [Related]

  • 38. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.
    Malik MA, Menon P, Rao KL, Samujh R.
    J Pediatr Surg; 2013 Dec 19; 48(12):2453-9. PubMed ID: 24314186
    [Abstract] [Full Text] [Related]

  • 39. Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers.
    Celik A, Tiryaki S, Musayev A, Kismali E, Levent E, Ergun O.
    J Drugs Dermatol; 2012 Jul 19; 11(7):808-11. PubMed ID: 22777220
    [Abstract] [Full Text] [Related]

  • 40. [Infantile hemangioma and propranolol: a therapeutic "revolution". Literature review].
    Yilmaz L, Dangoisse C, Semaille P.
    Rev Med Brux; 2013 Jul 19; 34(6):479-84. PubMed ID: 24505868
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.